Korjuny, a medication approved by the European Medicines Agency, is used for the intraperitoneal treatment of malignant ascites in patients not eligible for further systemic anticancer therapy. The medication contains catumaxomab, a monoclonal bispecific trifunctional antibody that targets tumor cells and T cells. Clinical trials have shown that Korjuny reduces the need for paracenteses in patients with malignant ascites, especially in those with gastric cancer. The medication has shown to be safe and effective in reducing symptoms of ascites and improving overall survival. Additionally, studies have confirmed that a re-challenge with Korjuny is feasible and safe for selected patients with recurrent malignant ascites. Common side effects of the medication include pyrexia, abdominal pain, nausea, and vomiting.
Source link
EMA Authorizes Korjuny for Malignant Ascites
